Genmab A (GMAB) Net Cash Flow Growth (1y) (2019 - 2026)
Genmab A (GMAB) Net Cash Flow Growth (1y) (2019 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
NCF Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
723,416.35 Bn |
723,416.32 Bn |
- |
- |
| 2 |
Belite Bio |
57,340.00 Bn |
57,340.00 Bn |
- |
- |
| 3 |
Quantum Biopharma |
19,125.08 Bn |
19,125.08 Bn |
- |
198.34% |
| 4 |
Legend Biotech |
3,262.00 Bn |
3,261.71 Bn |
242.10 Mn |
467.41% |
| 5 |
Akari Therapeutics |
1,789.67 Bn |
1,789.67 Bn |
- |
-14,223.53% |
| 6 |
Evaxion A |
1,480.39 Bn |
1,480.37 Bn |
- |
- |
| 7 |
Psyence Biomedical |
241.78 Bn |
241.78 Bn |
- |
- |
| 8 |
Vertex Pharmaceuticals |
113.54 Bn |
106.29 Bn |
2.59 Bn |
453.08% |
| 9 |
Abivax |
94.26 Bn |
94.26 Bn |
- |
- |
| 10 |
Genmab A |
48.34 Bn |
46.82 Bn |
831.00 Mn |
-179.22% |
| Date | Value |
|---|
| Mar 31, 2026 |
-179.22% |
| Sep 30, 2025 |
65.23% |
| Jun 30, 2025 |
94.45% |
| Mar 31, 2025 |
403.95% |
| Dec 31, 2024 |
59.01% |
| Sep 30, 2020 |
-100.00% |
| Dec 31, 2019 |
-100.00% |
